Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis (AD). The phase 2a study involved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback